Plain-English translation of NCT03065244 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Kawasaki disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested whether , a medication that reduces inflammation in the body, was more effective than a second dose of the standard intravenous immunoglobulin () treatment for children with Kawasaki disease whose fever did not go away after their first infusion. Kawasaki disease is a serious childhood condition that causes inflammation and can damage the heart if not treated quickly. Researchers wanted to see if this medication could help children whose bodies did not respond to the standard first-line treatment.
Some children with Kawasaki disease continue to have fever even after receiving the standard treatment, and their condition becomes harder to manage. This trial was designed to find out whether a different type of medication could work better for these children who don't respond to the usual approach.
If you were enrolled, you would have been randomly assigned to receive either a second dose of the standard treatment given through an IV over about 8 to 10 hours, or an infusion of the new medication given through an IV over about 2 hours. The trial measured whether your fever stopped within 24 hours, tracked blood work and heart imaging (echocardiogram) to see how quickly inflammation went down, and followed your progress over the following weeks.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States